Fakta om udbudet
EU-nr
2015/S 192-347690
Offentliggjort
05.10.2015
Udbyder
University of Copenhagen
Vindere
(05.10.2015)
Techtum Lab AB
Yrkesvägen 5
SE-904 20 Umeå, Sverige
Acquisition of a SensiQ Pioneer FE to Dept. of Drug Design and Pharmacology, University of Copenhagen
University of Copenhagen
Voluntary ex ante transparency notice
This notice is covered by: Directive 2004/18/EC
Section I: Contracting authority/entity
I.1) Name, addresses and contact point(s)
University of Copenhagen
Nørregade 10
For the attention of: Caroline Volf
1017 København K
DENMARK
Telephone: +45 35334470
E-mail: caroline.volf@adm.ku.dk
Internet address(es):
General address of the contracting authority/entity: http://www.indkoeb.ku.dk
I.2) Type of the contracting authority
Body governed by public law
I.3) Main activity
Other: university
1.4) Contract award on behalf of other contracting authorities/entities
The contracting authority/entity is purchasing on behalf of other contracting authorities/entities: no
Section II: Object of the contract
II.1) Description
II.1.1) Title attributed to the contract
Acquisition of a SensiQ Pioneer FE to Dept. of Drug Design and Pharmacology, University of Copenhagen.
II.1.2) Type of contract and location of works, place of delivery or of performance
Supplies
Purchase
Purchase
NUTS code DK011
II.1.3) Information about a framework agreement or a dynamic purchasing system (DPS)
II.1.4) Short description of the contract or purchase(s)
The SensiQ Pioneer FE is based on the technology of Surface Plasmon Resonance (SPR). The machine will enable us to test and screen small molecules (‘fragments’) against proteins (drug targets) and will be a key instrument for a new research group. The specific instrument is very sensitive, designed specifically for fragment screening (FE = Fragment edition), has unique and optimized software, and importantly and uniquely it is possible to do Taylor injection (OneStep technology). The latter allows to obtain Kd values (affinity constants) already at the screening step. In contrast, when using other SPR machines (e.g. Biacore), a special Kd determination would have to be done afterwards. So overall, you obtain Kd values from 1 injection (5 minutes) instead of 12 injections (1 hour), which makes a huge difference in the workflow and throughput. SensiQ is the only machine offering and combining these features.
II.1.5) Common procurement vocabulary (CPV)
38430000
II.6) Information about Government Procurement Agreement (GPA)
The contract is covered by the Government Procurement Agreement (GPA): yes
II.2) Total final value of contract(s)
II.2.1) Total final value of contract(s)
Value: 1 299 000 DKK
Excluding VAT
Excluding VAT
Section IV: Procedure
IV.1) Type of procedure
Award of a contract without prior publication of a contract notice in the Official Journal of the European Union (in the cases listed in Section 2 of Annexes D1, D2 or D3 as appropriate)
Justification for the choice of the negotiated procedure without prior publication of a contract notice in the OJEU in accordance with Directive 2004/18/EC
The products involved are manufactured purely for the purpose of research, experiment, study or development under the conditions stated in the Directive: yes
The works/goods/services can be provided only by a particular tenderer for reasons that are: technical
According to the European Parliament and Council Directive No. 2004/18 / EC, Article 31. 1, point b, the University of Copenhagen believes that SensiQ is the first to include OneStep technology in a SPR apparatus and still obtain high sensitivity. The SensiQ Pioneer FE is based on the technology of Surface Plasmon Resonance (SPR). The machine will enable testing and screening of small molecules (‘fragments’) against proteins (drug targets) and will be a key instrument for new research group. The specific instrument is very sensitive, designed specifically for fragment screening (FE = Fragment edition), has unique and optimized software, and importantly and uniquely it is possible to do Taylor injection (OneStep technology). The latter allows to obtain Kd values (affinity constants) already at the screening step. In contrast, when using other SPR machines (e.g. Biacore) special Kd determination would need to be done afterwards. So overall, you obtain Kd values from 1 injection (5 minutes) instead of 12 injections (1 hour), which makes a huge difference in the workflow and throughput. SensiQ is the only machine offering and combining these features. Their technology is very patented.
Justification for the choice of the negotiated procedure without prior publication of a contract notice in the OJEU in accordance with Directive 2004/18/EC
The products involved are manufactured purely for the purpose of research, experiment, study or development under the conditions stated in the Directive: yes
The works/goods/services can be provided only by a particular tenderer for reasons that are: technical
According to the European Parliament and Council Directive No. 2004/18 / EC, Article 31. 1, point b, the University of Copenhagen believes that SensiQ is the first to include OneStep technology in a SPR apparatus and still obtain high sensitivity. The SensiQ Pioneer FE is based on the technology of Surface Plasmon Resonance (SPR). The machine will enable testing and screening of small molecules (‘fragments’) against proteins (drug targets) and will be a key instrument for new research group. The specific instrument is very sensitive, designed specifically for fragment screening (FE = Fragment edition), has unique and optimized software, and importantly and uniquely it is possible to do Taylor injection (OneStep technology). The latter allows to obtain Kd values (affinity constants) already at the screening step. In contrast, when using other SPR machines (e.g. Biacore) special Kd determination would need to be done afterwards. So overall, you obtain Kd values from 1 injection (5 minutes) instead of 12 injections (1 hour), which makes a huge difference in the workflow and throughput. SensiQ is the only machine offering and combining these features. Their technology is very patented.
IV.2) Award criteria
IV.2.1) Award criteria
IV.2.2) Information about electronic auction
An electronic auction will be used: no
IV.3) Administrative information
IV.3.1) File reference number attributed by the contracting authority/entity
043-0168-15-7000
IV.3.2) Previous publication(s) concerning the same contract
no
Section V: Award of contract
V.1) Date of contract award decision:
V.2) Information about offers
V.3) Name and address of economic operator in favour of whom the contract award decision has been taken
Techtum Lab AB
Yrkesvägen 5
SE-904 20 Umeå
SWEDEN
E-mail: evefors@techtum.se
Telephone: +46 90778880
Internet address: http://www.techtum.se
V.4) Information on value of contract
V.5) Information about subcontracting
The contract is likely to be sub-contracted: no
Section VI: Complementary information
VI.1) Information about European Union funds
The contract is related to a project and/or programme financed by European Union funds: no
VI.2) Additional information:
Faculty of Health and Medical Sciences, Department of Drug Design and Pharmacology, is a part of University of Copenhagen.
VI.3) Procedures for appeal
VI.3.1) Body responsible for appeal procedures
Klagenævnet for udbud
Dahlerups Pakhus, Langelinie Allé 17
2100 København Ø
DENMARK
E-mail: klfu@erst.dk
Telephone: +45 35291000
Internet address: http://www.klfu.dk
VI.3.2) Lodging of appeals
Precise information on deadline(s) for lodging appeals A complaint against the contracting entity who, in accordance with the European Parliament and Council Directive No 2004/18/EC, Article 31, has decided to award a contract without prior publication of a contract notice in the Official Journal of the European Union must,in accordance with the Danish act on enforcement of procurement rules, etc. § 7, para. 3, be filed to the Danish Public procurement Appeal Board within 30 calendar days from the day following the day on which a contract notice is published in the Official Journal of the European Union.
The Danish act on enforcement of procurement rules, etc. defines in § 3, para. 1, point 1, a standstill period of 10 calendar days from the day after the date on which the voluntary ex ante transparency notice is published in the Official Journal of the European Union.
Latest at the same time as a complaint is lodged to the Danish Public procurement Appeal Board, the appellant shall in writing inform the contracting entity about the lodging of a complaint to the Danish Public procurement Appeal Board, and whether the complaint has been submitted in the stand still period. In cases where the complaint is not submitted in the stand still period, the appellant must specify any suspensive effect of the complaint according to The Danish act on enforcement of procurement rules § 12, Para. 1.
The Danish act on enforcement of procurement rules, etc. defines in § 3, para. 1, point 1, a standstill period of 10 calendar days from the day after the date on which the voluntary ex ante transparency notice is published in the Official Journal of the European Union.
Latest at the same time as a complaint is lodged to the Danish Public procurement Appeal Board, the appellant shall in writing inform the contracting entity about the lodging of a complaint to the Danish Public procurement Appeal Board, and whether the complaint has been submitted in the stand still period. In cases where the complaint is not submitted in the stand still period, the appellant must specify any suspensive effect of the complaint according to The Danish act on enforcement of procurement rules § 12, Para. 1.
VI.3.3) Service from which information about the lodging of appeals may be obtained
Konkurrence- og Forbrugerstyrelsen
Carl Jacobsens Vej 35, Valby
2500 København
DENMARK
E-mail: kfst@kfst.dk
Telephone: +45 41715000
Internet address: http://www.kfst.dk
VI.4) Date of dispatch of this notice:
30.9.2015